CoChat

VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study

Guandalini, Stefano, Magazzù, Giuseppe, Chiaro, Andrea, La Balestra, Valeria, Di Nardo, Giovanni, Gopalan, Sarath, Sibal, A, Romano, Claudio, Canani, Roberto Berni, Lionetti, Paolo, Setty, Mala · 2010 · Journal of Pediatric Gastroenterology and Nutrition

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Background and Objectives: Irritable bowel syndrome (IBS) is a common problem in pediatrics, for which no safe and effective treatment is available. Probiotics have shown some promising results in adult studies, but no positive study has been published on pediatric age. We aimed at investigating the efficacy of VSL#3 in a population of children and teenagers affected by IBS, in a randomized, double‐blind, placebo‐controlled, crossover study conducted in 7 pediatric gastroenterology divisions. Patients and Methods: Children 4 to 18 years of age, meeting eligibility criteria, were enrolled. The patients were assessed by a questionnaire for a 2‐week baseline period. They were then randomized to receive either VSL#3 or a placebo for 6 weeks, with controls every 2 weeks. At the end, after a “wash‐out” period of 2 weeks, each patient was switched to the other group and followed for a further 6 weeks. Results: A total of 59 children completed the study. Although placebo was effective in some of the parameters and in as many as half of the patients, VSL#3 was significantly superior to it ( P < 0.05) in the primary endpoint, the subjective assessment of relief of symptoms; as well as in 3 of 4 secondary endpoints: abdominal pain/discomfort ( P < 0.05), abdominal bloating/gassiness ( P < 0.05), and family assessment of life disruption ( P < 0.01). No significant difference was found ( P = 0.06) in the stool pattern. No untoward adverse effect was recorded in any of the patients. Conclusions: VSL#3 is safe and more effective than placebo in ameliorating symptoms and improving the quality of life in children affected by IBS.

Overview

Integrity signals

Registry

Crossref · 10.1097/mpg.0b013e3181ca4d95

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

2 retracted

Show all 32 references

Cited by

Items 101–200 of 273

Metadata

Authors
Guandalini, S., Magazzù, G., Chiaro, A., La Balestra, V., Di Nardo, G., Gopalan, S., Sibal, A., Romano, C., Canani, R. B., Lionetti, P., & Setty, M.
Affiliations
  • University of Chicago (US)
  • University of Messina (IT)
  • University of Rome “La Sapienza” Rome Italy
  • CRNSS New Delhi India
  • Federico II University Hospital (IT)
  • University of Florence (IT)
Corresponding author
  • Guandalini, Stefano
  • Setty, Mala
Venue
Journal of Pediatric Gastroenterology and Nutrition
Publisher
Wiley
Published
2010-07
Volume
51
Issue
1
Pages
24-30
ISSN
  • 0277-2116 (ISSN-L)
  • 1536-4801
OpenAlex
W2005532504
Cited by
273
References
32
Citations by year
2026: 8 · 2025: 6 · 2024: 15 · 2023: 11 · 2022: 20 · 2021: 17 · 2020: 15 · 2019: 12 · 2018: 24 · 2017: 13 · 2016: 20 · 2015: 19 · 2014: 23 · 2013: 22 · 2012: 24
FWCI
23.03
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Pediatric Gastroenterology and Nutrition (publishedVersion)
  • PubMed (publishedVersion)
  • Florence Research (University of Florence) (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
Keywords
irritable bowel syndrome, VSL#3, probiotics, children, adolescents, symptom relief, abdominal pain, bloating, quality of life, placebo comparison
MeSH terms
Adolescent, Child, Child, Preschool, Double-Blind Method, Family, Female, Humans, Male, Surveys and Questionnaires, Abdominal Pain, Treatment Outcome, Cross-Over Studies, Probiotics, Irritable Bowel Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.